


## Claims

1. A compound of formula I



wherein

$R^1$  is  $-(CH_2)_n-CO-NR^5R^6$ ;  $-(CH_2)_n-COOR^7$ ;  $-(CH_2)_n-NR^5R^6$ ;  $-(CH_2)_n-CN$ ;  $-(CH_2)_n-OR^8$ ; or phenyl, which is unsubstituted or substituted by one to three substituents selected from halogen and fluoro( $C_1-C_6$ )-alkyl;

$R^2$  is hydrogen, halogen or  $C_1-C_6$ -alkyl;

$R^3$  is hydrogen,  $C_1-C_6$ -alkyl,  $C_3-C_6$ -cycloalkyl or benzyl;

$R^4$  is halogen, fluoro( $C_1-C_6$ )-alkyl, cyano,  $C_1-C_6$ -alkoxy or fluoro( $C_1-C_6$ )-alkoxy;

$R^5$  and  $R^6$  are independently from each other hydrogen or  $C_1-C_6$ -alkyl;

$R^7$  is hydrogen or  $C_1-C_6$ -alkyl;

$R^8$  is hydrogen or  $C_1-C_6$ -alkyl;

$m$  is 1, 2 or 3; and

$n$  is 0, 1 or 2;

or a pharmaceutically acceptable salt thereof.

2. The compound of formula I according to claim 1 wherein

$R^1$  is  $-(CH_2)_n-CO-NR^5R^6$ ;  $-(CH_2)_n-COOR^7$ ;  $-(CH_2)_n-NR^5R^6$ ;  $-(CH_2)_n-CN$ ;  $-(CH_2)_n-OR^8$ ; or phenyl, which is unsubstituted or substituted by one to three substituents selected from halogen and fluoro( $C_1-C_6$ )-alkyl;

$R^2$  is hydrogen or  $C_1-C_6$ -alkyl;

$R^3$  is hydrogen,  $C_1-C_6$ -alkyl,  $C_3-C_6$ -cycloalkyl or benzyl;

$R^4$  is halogen, fluoro( $C_1-C_6$ )-alkyl, cyano,  $C_1-C_6$ -alkoxy or fluoro( $C_1-C_6$ )-alkoxy;

$R^5$  and  $R^6$  are independently from each other hydrogen or  $C_1-C_6$ -alkyl;

$R^7$  is hydrogen or  $C_1-C_6$ -alkyl;

R<sup>8</sup> is hydrogen or C<sub>1</sub>-C<sub>6</sub>-alkyl;  
m is 1, 2 or 3; and  
n is 0, 1 or 2;  
or a pharmaceutically acceptable salt.

3. The compound of formula I according to claim 1 wherein R<sup>1</sup> is -(CH<sub>2</sub>)<sub>n</sub>-CO-NR<sup>5</sup>R<sup>6</sup>; -(CH<sub>2</sub>)<sub>n</sub>-COOR<sup>7</sup>; -(CH<sub>2</sub>)<sub>n</sub>-NR<sup>5</sup>R<sup>6</sup>; -(CH<sub>2</sub>)<sub>n</sub>-CN; -(CH<sub>2</sub>)<sub>n</sub>-OR<sup>8</sup>; or phenyl, which is unsubstituted or substituted by one to three substituents selected from halogen and fluoro(C<sub>1</sub>-C<sub>6</sub>)-alkyl;

R<sup>2</sup> is halogen or C<sub>1</sub>-C<sub>6</sub>-alkyl;  
R<sup>3</sup> is hydrogen, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>3</sub>-C<sub>6</sub>-cycloalkyl or benzyl;  
R<sup>4</sup> is halogen, fluoro(C<sub>1</sub>-C<sub>6</sub>)-alkyl, cyano, C<sub>1</sub>-C<sub>6</sub>-alkoxy or fluoro(C<sub>1</sub>-C<sub>6</sub>)-alkoxy;  
R<sup>5</sup> and R<sup>6</sup> are independently from each other hydrogen or C<sub>1</sub>-C<sub>6</sub>-alkyl;  
R<sup>7</sup> is hydrogen or C<sub>1</sub>-C<sub>6</sub>-alkyl;  
R<sup>8</sup> is hydrogen or C<sub>1</sub>-C<sub>6</sub>-alkyl;  
m is 1, 2 or 3; and  
n is 0, 1 or 2;  
or a pharmaceutically acceptable salt thereof.

4. The compound of formula I according to claim 1 wherein R<sup>1</sup> is -(CH<sub>2</sub>)<sub>n</sub>-CO-NR<sup>5</sup>R<sup>6</sup>; -(CH<sub>2</sub>)<sub>n</sub>-COOR<sup>7</sup>; -(CH<sub>2</sub>)<sub>n</sub>-NR<sup>5</sup>R<sup>6</sup>; -(CH<sub>2</sub>)<sub>n</sub>-CN; -(CH<sub>2</sub>)<sub>n</sub>-OR<sup>8</sup>; or phenyl, which is unsubstituted or substituted by one to three substituents selected from halogen and fluoro(C<sub>1</sub>-C<sub>6</sub>)-alkyl;

R<sup>2</sup> is hydrogen, halogen or C<sub>1</sub>-C<sub>6</sub>-alkyl;  
R<sup>3</sup> is hydrogen or C<sub>1</sub>-C<sub>6</sub>-alkyl,  
R<sup>4</sup> is halogen, fluoro(C<sub>1</sub>-C<sub>6</sub>)-alkyl, cyano, C<sub>1</sub>-C<sub>6</sub>-alkoxy or fluoro(C<sub>1</sub>-C<sub>6</sub>)-alkoxy;  
R<sup>5</sup> and R<sup>6</sup> are independently from each other hydrogen or C<sub>1</sub>-C<sub>6</sub>-alkyl;  
R<sup>7</sup> is hydrogen or C<sub>1</sub>-C<sub>6</sub>-alkyl;  
R<sup>8</sup> is hydrogen or C<sub>1</sub>-C<sub>6</sub>-alkyl;  
m is 1, 2 or 3; and  
n is 0, 1 or 2;  
or a pharmaceutically acceptable salt thereof.

5. The compound of formula I according to claim 1 wherein  
 $R^1$  is  $-(CH_2)_n-CO-NR^5R^6$ ;  $-(CH_2)_n-COOR^7$ ;  $-(CH_2)_n-NR^5R^6$ ;  $-(CH_2)_n-CN$ ;  $-(CH_2)_n-OR^8$ ; or phenyl, which is unsubstituted or substituted by one to three substituents selected from halogen and fluoro( $C_1-C_6$ )-alkyl;  
 $R^2$  is hydrogen, halogen or  $C_1-C_6$ -alkyl;  
 $R^3$  is  $C_3-C_6$ -cycloalkyl or benzyl;  
 $R^4$  is halogen, fluoro( $C_1-C_6$ )-alkyl, cyano,  $C_1-C_6$ -alkoxy or fluoro( $C_1-C_6$ )-alkoxy;  
 $R^5$  and  $R^6$  are independently from each other hydrogen or  $C_1-C_6$ -alkyl;  
 $R^7$  is hydrogen or  $C_1-C_6$ -alkyl;  
 $R^8$  is hydrogen or  $C_1-C_6$ -alkyl;  
 $m$  is 1, 2 or 3; and  
 $n$  is 0, 1 or 2;  
or a pharmaceutically acceptable salt thereof.

6. The compound of formula I according to claim 1 wherein  
 $R^1$  is  $-(CH_2)_n-CO-NH_2$ ;  $-(CH_2)_n-COOR^7$ ;  $-(CH_2)_n-NH_2$ ;  $-(CH_2)_n-CN$ ;  $-(CH_2)_n-OR^8$ ; or phenyl, which is unsubstituted or substituted by one to three substituents selected from halogen and fluoro( $C_1-C_6$ )-alkyl;  
 $R^2$  is hydrogen, halogen or  $C_1-C_6$ -alkyl;  
 $R^3$  is hydrogen,  $C_1-C_6$ -alkyl,  $C_3-C_6$ -cycloalkyl or benzyl;  
 $R^4$  is halogen, fluoro( $C_1-C_6$ )-alkyl, cyano,  $C_1-C_6$ -alkoxy or fluoro( $C_1-C_6$ )-alkoxy;  
 $R^5$  and  $R^6$  are independently from each other hydrogen or  $C_1-C_6$ -alkyl;  
 $R^7$  is hydrogen or  $C_1-C_6$ -alkyl;  
 $R^8$  is hydrogen or  $C_1-C_6$ -alkyl;  
 $m$  is 1, 2 or 3; and  
 $n$  is 0, 1 or 2;  
or a pharmaceutically acceptable salt thereof.

7. The compound of formula I according to claim 1 wherein  
 $R^1$  is  $-(CH_2)_n-CO-NR^5R^6$ ;  $-(CH_2)_n-COOR^7$ ;  $-(CH_2)_n-NR^5R^6$ ;  $-(CH_2)_n-CN$ ;  $-(CH_2)_n-OR^8$ ; or phenyl, which is unsubstituted or substituted by one to three substituents selected from halogen and fluoro( $C_1-C_6$ )-alkyl;  
 $R^2$  is hydrogen, halogen or  $C_1-C_6$ -alkyl;

$R^3$  is hydrogen,  $C_1$ - $C_6$ -alkyl,  $C_3$ - $C_6$ -cycloalkyl or benzyl;  
 $R^4$  is halogen, fluoro( $C_1$ - $C_6$ )-alkyl;  
 $R^5$  and  $R^6$  are independently from each other hydrogen or  $C_1$ - $C_6$ -alkyl;  
 $R^7$  is hydrogen or  $C_1$ - $C_6$ -alkyl;  
 $R^8$  is hydrogen or  $C_1$ - $C_6$ -alkyl;  
 $m$  is 1, 2 or 3; and  
 $n$  is 0, 1 or 2;  
 or a pharmaceutically acceptable salt thereof.

8. The compound of formula I according to claim 1 wherein  
 $R^1$  is  $-(CH_2)_n-CO-NR^5R^6$ ;  $-(CH_2)_n-COOR^7$ ;  $-(CH_2)_n-NR^5R^6$ ;  $-(CH_2)_n-CN$ ;  $-(CH_2)_n-OR^8$ ; or phenyl, which is unsubstituted or substituted by one to three substituents selected from halogen and fluoro( $C_1$ - $C_6$ )-alkyl;  
 $R^2$  is hydrogen, halogen or  $C_1$ - $C_6$ -alkyl;  
 $R^3$  is hydrogen,  $C_1$ - $C_6$ -alkyl,  $C_3$ - $C_6$ -cycloalkyl or benzyl;  
 $R^4$  is  $C_1$ - $C_6$ -alkoxy or fluoro( $C_1$ - $C_6$ )-alkoxy;  
 $R^5$  and  $R^6$  are independently from each other hydrogen or  $C_1$ - $C_6$ -alkyl;  
 $R^7$  is hydrogen or  $C_1$ - $C_6$ -alkyl;  
 $R^8$  is hydrogen or  $C_1$ - $C_6$ -alkyl;  
 $m$  is 1, 2 or 3; and  
 $n$  is 0, 1 or 2;  
 or a pharmaceutically acceptable salt thereof.

9. The compound of formula I according to claim 1 wherein  $R^1$  is  $-(CH_2)_n-CO-NR^5R^6$ .

10. The compound of formula I according to claim 1 wherein  $R^1$  is  $-(CH_2)_n-COOR^7$ .

11. The compound of formula I according to claim 1 wherein  $R^1$  is  $-(CH_2)_n-NR^5R^6$ .

12. The compound of formula I according to claim 1 wherein  $R^1$  is  $-(CH_2)_n-CN$ .

13. The compound of formula I according to claim 1 wherein  $R^1$  is  $-(CH_2)_n-$  OR<sup>8</sup>.
14. The compound of formula I according to claim 1 wherein  $R^1$  is phenyl, which is unsubstituted or substituted by one to three substituents selected from halogen and fluoro( $C_1$ - $C_6$ )-alkyl.
15. The compound of formula I according to claim 14 wherein said phenyl is substituted by halogen.
16. The compound of formula I according to claim 1 wherein  $R^2$  is hydrogen.
17. The compound of formula I according to claim 1 wherein  $R^2$  is halogen.
18. The compound of formula I according to claim 1 wherein  $R^2$  is  $C_1$ - $C_6$ -alkyl.
19. The compound of formula I according to claim 1 wherein  $R^3$  is hydrogen.
20. The compound of formula I according to claim 1 wherein  $R^3$  is  $C_1$ - $C_6$ -alkyl.
21. The compound of formula I according to claim 1 wherein  $R^3$  is  $C_3$ - $C_6$ -cycloalkyl.
22. The compound of formula I according to claim 1 wherein  $R^3$  is benzyl.
23. The compound of formula I according to claim 1 wherein  $R^3$  is hydrogen,  $C_1$ - $C_6$ -alkyl,  $C_3$ - $C_6$ -cycloalkyl or benzyl.
24. The compound of formula I according to claim 1 wherein  $R^4$  is halogen or fluoro( $C_1$ - $C_6$ )-alkyl.
25. The compound of formula I according to claim 1 wherein  $R^4$  is cyano.


26. The compound of formula I according to claim 1 wherein R<sup>4</sup> is C<sub>1</sub>-C<sub>6</sub>-alkoxy or fluoro(C<sub>1</sub>-C<sub>6</sub>)-alkoxy.
27. The compound of formula I according to claim 1 wherein R<sup>7</sup> is hydrogen.
28. The compound of formula I according to claim 1 wherein R<sup>7</sup> is (C<sub>1</sub>-C<sub>6</sub>)-alkyl.
29. A compound of formula I according to claim 1 selected from  
2-[7-(3-fluoro-benzyloxy)-4-oxo-4H-quinazolin-3-yl]-acetamide,  
2-[7-(3-fluoro-benzyloxy)-4-oxo-4H-quinazolin-3-yl]-propionamide,  
2-[7-(4-fluoro-benzyloxy)-4-oxo-4H-quinazolin-3-yl]-acetamide,  
2-[7-(4-fluoro-benzyloxy)-4-oxo-4H-quinazolin-3-yl]-propionamide,  
2-[7-(3-fluoro-benzyloxy)-2-methyl-4-oxo-4H-quinazolin-3-yl]-acetamide, and  
2-[2-cyclopropyl-7-(3-fluoro-benzyloxy)-4-oxo-4H-quinazolin-3-yl]-acetamide.
30. A compound of formula I according to claim 1 selected from  
7-(3-fluoro-benzyloxy)-3-(2-methoxy-ethyl)-3H-quinazolin-4-one,  
7-(4-fluoro-benzyloxy)-3-(2-methoxy-ethyl)-3H-quinazolin-4-one,  
7-(3-fluoro-benzyloxy)-3-(2-methoxy-ethyl)-2-methyl-3H-quinazolin-4-one,  
3-(2-amino-ethyl)-7-(3-fluoro-benzyloxy)-3H-quinazolin-4-one 1:2 hydrochloride,  
3-(3-amino-propyl)-7-(3-fluoro-benzyloxy)-3H-quinazolin-4-one 1:2 hydrochloride,  
3-(2-amino-ethyl)-7-(4-fluoro-benzyloxy)-3H-quinazolin-4-one 1:1 hydrochloride, and  
2-[7-(3-fluoro-benzyloxy)-2-methyl-4-oxo-4H-quinazolin-3-yl]-ethyl-ammonium chloride.
31. A compound of formula I according to claim 1 selected from  
[7-(3-fluoro-benzyloxy)-4-oxo-4H-quinazolin-3-yl]-acetic acid ethyl ester;  
fluoro-[7-(3-fluoro-benzyloxy)-4-oxo-4H-quinazolin-3-yl]-acetic acid ethyl ester;  
2-[7-(3-fluoro-benzyloxy)-4-oxo-4H-quinazolin-3-yl]-propionic acid ethyl ester;

[7-(3-fluoro-benzyloxy)-4-oxo-4H-quinazolin-3-yl]-acetic acid tert-butyl ester;  
 2-[7-(3-fluoro-benzyloxy)-4-oxo-4H-quinazolin-3-yl]-propionic acid tert-butyl ester;  
 [7-(4-fluoro-benzyloxy)-4-oxo-4H-quinazolin-3-yl]-acetic acid ethyl ester; and  
 2-[7-(4-fluoro-benzyloxy)-4-oxo-4H-quinazolin-3-yl]-propionic acid ethyl ester.

32. A compound of formula I according to claim 1 selected from  
 3-(3-fluoro-benzyl)-7-(3-fluoro-benzyloxy)-3H-quinazolin-4-one;  
 3-[7-(4-fluoro-benzyloxy)-4-oxo-4H-quinazolin-3-yl]-propionamide;  
 2-[7-(3-fluoro-benzyloxy)-2-isopropyl-4-oxo-4H-quinazolin-3-yl]-acetamide;  
 [7-(3-fluoro-benzyloxy)-2-isopropyl-4-oxo-4H-quinazolin-3-yl]-acetonitrile;  
 2-cyclopropyl-7-(3-fluoro-benzyloxy)-3-(2-methoxy-ethyl)-3H-quinazolin-4-one;  
 [2-cyclopropyl-7-(3-fluoro-benzyloxy)-4-oxo-4H-quinazolin-3-yl]-acetic acid methyl ester; and  
 2-[2-benzyl-7-(3-fluoro-benzyloxy)-4-oxo-4H-quinazolin-3-yl]-acetamide.

33. A pharmaceutical composition comprising a compound of formula I according to claim 1 and a pharmaceutically acceptable carrier.

34. A process for the preparation of a compound of formula I according to claim 1 comprising reacting a compound of formula IV




wherein

R<sup>3</sup> is hydrogen, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>3</sub>-C<sub>6</sub>-cycloalkyl or benzyl;

R<sup>4</sup> is halogen, fluoro(C<sub>1</sub>-C<sub>6</sub>)-alkyl, cyano, C<sub>1</sub>-C<sub>6</sub>-alkoxy or fluoro(C<sub>1</sub>-C<sub>6</sub>)-alkoxy; and

m is 1, 2 or 3

with a compound of formula V



wherein

$R^1$  is  $-(CH_2)_n-CO-NR^5R^6$ ;  $-(CH_2)_n-COOR^7$ ;  $-(CH_2)_n-NR^5R^6$ ;  $-(CH_2)_n-CN$ ;  $-(CH_2)_n-OR^8$ ; or phenyl, which is unsubstituted or substituted by one to three substituents selected from halogen and fluoro( $C_1-C_6$ )-alkyl;

$R^2$  is hydrogen, halogen or  $C_1-C_6$ -alkyl;

$R^5$  and  $R^6$  are independently from each other hydrogen or  $C_1-C_6$ -alkyl;

$R^7$  is hydrogen or  $C_1-C_6$ -alkyl;

$R^8$  is hydrogen or  $C_1-C_6$ -alkyl; and

$n$  is 0, 1 or 2.

35. A method of treating Alzheimer's disease in an individual comprising administering to the individual an effective amount of a compound according to claim 1.

36. A method of treating senile dementia in an individual comprising administering to the individual an effective amount of a compound according to claim 1.

37. A method of treating Parkinson's disease in an individual comprising administering to the individual an effective amount of a compound according to claim 1.